COVID-19 mRNA vaccines: Platforms and current developments

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine agent in a preclinical study nearly 30 years ago, numerous advances have been made in the field of mRNA therapeutic technologies. This research uncovered the unique favorable characteristics of mRNA vaccines, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Szabó, Gábor Tamás, Mahiny, Azita Josefine, Vlatkovic, Irena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856755/
https://www.ncbi.nlm.nih.gov/pubmed/35189345
http://dx.doi.org/10.1016/j.ymthe.2022.02.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856755/
https://www.ncbi.nlm.nih.gov/pubmed/35189345
http://dx.doi.org/10.1016/j.ymthe.2022.02.016

Ejemplares similares